Freenome
Spot the pattern. Treat the cancer.
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
Some members of the team work remotely, while others are co-located in one or more offices.
💼Healthcare
👥201-500
📍South San Francisco, CA
Freenome

About Freenome

About Freenome
About Freenome
Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.

What Freenome is building

Freenome product / service
Freenome product / service
Freenome product / service
Freenome product / service
Freenome product / service
Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
See more

Technologies used at Freenome

Back-end (5)
Front-end (1)
AWSAWS
PythonPython
DockerDocker
PostgreSQLPostgreSQL
SQLSQL

Company culture

Culture of Collaboration

At Freenome, we pride ourselves on the collaboration of our diverse team of clinicians, machine learning scientists, biologists, and business specialists.

See more

Funding roundsIconOpenNewWindows

Total Funding

Total Funding

$1.1B
Last funding round type

Last funding round type

Corporate Round
Company type

Company type

For Profit

Freenome news and updates

Freenome Inc. launched Sanderson Study on Sep 9th 22'.

Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the company’s latest study of its multiomics platform, in combination with real-world data to detect multiple cancers.

Sep 8, 2022 | repertoiremag.com

Freenome Inc. is developing CRC screening test using a routine blood draw to detect cancer in earliest stages

Freenome is developing a CRC screening test using a routine blood draw to detect cancer in its earliest stages.

Mar 14, 2022 | freenome.com

Freenome Inc. launched Vallania Study on Mar 4th 22'.

Freenome recently launched the Vallania Study, a clinical study to evaluate and extend the platform for the early detection of multiple cancers.

Jan 1, 2022 | freenome.com

Freenome Inc. partners with Merck KGaA

Freenome, a privately held biotech company, announced its co-authorship of a study with Merck KGaA, Darmstadt Germany, a leading science and technology company.

Jan 1, 2022 | yahoo.com

Freenome Inc. launched prospective clinical study on May 11th 22'.

Earlier this year, Freenome launched its first prospective clinical study for multi-cancer early detection with several partners from PREEMPT CRC.

Jan 1, 2022 | pharmtechfocus.com

Freenome Inc. hires Charles as senior vice president and chief financial officer for the Flash division

Charles joins Freenome from Western Digital where he was senior vice president and chief financial officer for the Flash division.

Jan 1, 2022 | prnewswire.com

Freenome Inc. partners with Haircutswithheart

Freenome Inc. partnered with Haircuts with Heart to provide hair & nail services (which was by far the most popular).

Jan 1, 2020 | freenome.com

Freenome Inc. hires Tzou as Chief Medical Officer

“Dr. Tzou joins Freenome at an exciting point in its growth and Freenome Inc. is pleased to welcome him to the team,” said Girish Putcha, M.D., Ph.D., Chief Medical Officer at Freenome.

Jan 1, 2017 | businesswire.com
See More